The interactions between PD-L1 and PD-1 have become a focal point in cancer immunotherapy [9, 10], and immune checkpoint blockades (ICBs) targeting the PD-L1/PD-1 axis demonstrate significant clinical efficacy in various malignancies [11–13]. The gene discussed is PDCD1; the disease is cancer.